Dan Ives, Wedbush Securities global head of technology research and senior equity analyst, joins 'Squawk Box' to discuss ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Equities researchers at Wedbush lifted their Q4 2025 earnings per share estimates for shares of CarMax in a research note ...

If the Department of Defense goes through budget cuts as suggested by a leaked memo, Palantir Technologies (PLTR) would have ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their Outperform rating and $550 price target on the stock. While concerns ...

In a report released today, Richard Anderson from Wedbush reiterated a Buy rating on RH (RH – Research Report), with a price target of $500.00.

Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for ...

Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...